ACRS Aclaris Therapeutics, Inc. Stock Quote

ACRS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.36	Insider Own	3.50%	Shs Outstand	42.80M	Perf Week	198.69%
Market Cap	873.10M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	0.00%	Shs Float	37.16M	Perf Month	201.66%
Income	-57.00M	PEG	-	EPS next Q	-0.27	Inst Own	66.10%	Short Float	1.85%	Perf Quarter	328.71%
Sales	6.00M	P/S	145.52	EPS this Y	-10.10%	Inst Trans	3.07%	Short Ratio	0.25	Perf Half Y	713.39%
Book/sh	0.95	P/B	19.18	EPS next Y	16.40%	ROA	-64.10%	Target Price	20.00	Perf Year	1038.75%
Cash/sh	1.11	P/C	16.35	EPS next 5Y	-	ROE	-103.50%	52W Range	0.70 - 24.28	Perf YTD	181.61%
Dividend	-	P/FCF	-	EPS past 5Y	-57.10%	ROI	-158.70%	52W High	-24.96%	Beta	1.36
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	18.70%	52W Low	2502.86%	ATR	1.96
Employees	77	Current Ratio	4.50	Sales Q/Q	40.00%	Oper. Margin	-	RSI (14)	86.35	Volatility	24.15% 13.24%
Optionable	Yes	Debt/Eq	0.27	EPS Q/Q	55.50%	Profit Margin	-	Rel Volume	0.50	Prev Close	18.04
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Nov 04 BMO	Payout	-	Avg Volume	2.79M	Price	18.22
Recom	1.20	SMA20	119.85%	SMA50	224.38%	SMA200	497.00%	Volume	1,385,070	Change	1.00%

Oct-22-19

Upgrade

SVB Leerink

Mkt Perform → Outperform

Sep-06-19

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Jun-27-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

May-06-19

Initiated

SVB Leerink

Outperform

$13

Mar-28-18

Resumed

Leerink Partners

Outperform

$52

Feb-09-18

Initiated

Guggenheim

Buy

$53

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$50

Nov-29-16

Initiated

Leerink Partners

Outperform

$54

Sep-30-16

Initiated

JMP Securities

Mkt Outperform

Jun-10-16

Initiated

Guggenheim

Buy

$35

Nov-02-15

Initiated

Jefferies

Buy

$20

Nov-02-15

Initiated

Citigroup

Buy

Jan-20-21 01:25PM	How High Is the Blue Sky for Aclaris Stock? Analyst Weighs In TipRanks
12:13PM	Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates Zacks
10:30AM	Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA Zacks
08:45AM	Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire
07:32AM	The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga
04:19AM	Aclaris Explodes 220% On Positive Data From Rheumatoid Arthritis Trial SmarterAnalyst
Jan-19-21 04:34PM	Aclaris Triples After Progress in Rheumatoid Arthritis Drug Trial TheStreet.com +220.24%
04:01PM	Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire
12:10PM	Aclaris Therapeutics stock more than triples after 'positive' data on arthritis treatment trial MarketWatch
07:00AM	Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis GlobeNewswire
Dec-28-20 11:17PM	Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load? Simply Wall St. -11.70%
Dec-23-20 09:11AM	Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options Zacks +8.13%
Dec-15-20 11:26PM	Is ACRS A Good Stock To Buy Now? Insider Monkey +16.79%
07:00AM	Aclaris Therapeutics Announces Formation of New Scientific Advisory Board GlobeNewswire
Nov-16-20 04:01PM	Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire -12.36%
Nov-14-20 07:08AM	How Much Does Aclaris Therapeutics' (NASDAQ:ACRS) CEO Make? Simply Wall St.
Nov-06-20 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know Zacks
Nov-04-20 08:25AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.47%
07:00AM	Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Oct-29-20 12:35PM	Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-21-20 10:46AM	Aclaris (ACRS) Begins Phase II Study on Eczema Candidate Zacks -5.97%
Oct-20-20 07:00AM	Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical Soft JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis GlobeNewswire
Oct-14-20 10:36PM	Hedge Funds Are Buying Aclaris Therapeutics, Inc. (ACRS) Insider Monkey
Oct-01-20 12:00PM	All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy Zacks
Sep-30-20 06:40AM	Could The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ownership Structure Tell Us Something Useful? Simply Wall St.
Sep-01-20 04:01PM	Aclaris Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -5.28%
Aug-13-20 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know Zacks
Aug-07-20 08:45AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Zacks +7.69%
07:00AM	Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights GlobeNewswire
Aug-06-20 12:30PM	Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know Zacks -9.30%
Jul-08-20 08:43AM	Aclaris (ACRS) Surges: Stock Moves 5.4% Higher Zacks
Jul-07-20 04:01PM	Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical Soft JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis GlobeNewswire +5.36%
Jun-26-20 02:30PM	Is Aclaris Therapeutics, Inc. (ACRS) A Good Stock To Buy? Insider Monkey
Jun-18-20 10:12AM	Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study Zacks
Jun-17-20 10:37AM	P/E Ratio Insights for Aclaris Therapeutics Benzinga +16.55%
07:01AM	Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19 GlobeNewswire
Jun-03-20 07:00AM	Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress GlobeNewswire
May-26-20 04:01PM	Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire +7.32%
May-12-20 10:47AM	Will Aclaris Therapeutics Continue to Surge Higher? Zacks
May-08-20 12:00PM	All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy Zacks
May-07-20 04:01PM	Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights GlobeNewswire +8.73%
May-06-20 12:30PM	Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-09-20 06:13AM	Does The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Share Price Fall With The Market? Simply Wall St.
Apr-06-20 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's Why Zacks
Apr-01-20 11:07AM	Wayne biopharma firm borrows $11M to fund new business strategy American City Business Journals
Mar-31-20 04:01PM	Aclaris Therapeutics Secures $11 Million Term Loan Facility GlobeNewswire
Mar-17-20 02:46AM	Edited Transcript of ACRS earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-25-20 04:01PM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights GlobeNewswire
Feb-24-20 07:31AM	Is Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Paid At A Competitive Rate? Simply Wall St.
Feb-19-20 05:00PM	Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 GlobeNewswire
Feb-10-20 07:00AM	Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire
Jan-13-20 05:03PM	Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I Zacks
Jan-10-20 07:13AM	The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga +17.20%
05:40AM	Some Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Have Taken A Painful 94% Share Price Drop Simply Wall St.
Jan-09-20 04:27PM	Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor GlobeNewswire
Jan-08-20 08:00AM	Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors GlobeNewswire
Dec-24-19 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's Why Zacks
Dec-12-19 10:33AM	Did Hedge Funds Drop The Ball On Aclaris Therapeutics, Inc. (ACRS) ? Insider Monkey
Nov-27-19 03:23PM	Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) Business Wire
Nov-21-19 11:39AM	Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) Business Wire -11.24%
Nov-18-19 05:34PM	Rigel Gets Positive CHMP Review for Thrombocytopenia Drug Zacks
Nov-17-19 07:14AM	Edited Transcript of ACRS earnings conference call or presentation 7-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:01PM	Aclaris Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-19 04:01PM	Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs GlobeNewswire
Oct-31-19 04:01PM	Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 GlobeNewswire
Oct-29-19 10:33AM	Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +14.46%
Oct-25-19 07:12AM	The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug Benzinga +5.95%
Oct-24-19 04:01PM	Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1) GlobeNewswire
Oct-17-19 09:46AM	Company News for Oct 17, 2019 Zacks +6.41%
Oct-14-19 10:28AM	Aclaris Divests Rhofade to EPI Health for $55M, Shares Up Zacks
Oct-11-19 11:46AM	Wayne biopharma sells rosacea therapy in deal that could bring in $55M American City Business Journals +19.33%
Oct-10-19 04:02PM	Aclaris Therapeutics Announces Divestiture of RHOFADE® GlobeNewswire
Oct-09-19 07:58AM	The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug Benzinga
Oct-08-19 05:01PM	Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1% GlobeNewswire
01:42PM	Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 07:25AM	Does Market Volatility Impact Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Share Price? Simply Wall St.
Oct-06-19 10:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm GlobeNewswire
Oct-03-19 07:28AM	Top Ranked Momentum Stocks to Buy for October 3rd Zacks
Sep-30-19 12:15PM	FINAL DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -9.24%
10:44AM	FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action ACRS GlobeNewswire
Sep-28-19 06:30PM	DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:00AM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm Business Wire
Sep-27-19 08:15PM	FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM	Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
12:21PM	Top Ranked Momentum Stocks to Buy for September 27th Zacks
11:00AM	DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:36AM	Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-26-19 04:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS PR Newswire -11.65%
04:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS CNW Group
11:17AM	Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire
08:19AM	Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue? Zacks
Sep-25-19 08:48PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm PR Newswire +6.83%
03:38PM	ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile
03:15PM	5-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:00AM	Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. GlobeNewswire
10:35AM	Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:00AM	Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade Zacks
Sep-24-19 09:10PM	6-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire
03:09PM	Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience